Jackie (on behalf of Brendan)'s questions to Abcellera Biologics Inc (ABCL) leadership • Q1 2025
Question
An analyst identified as Jackie asked about the specific Phase I data points ABCL635 needs to demonstrate a competitive edge against existing treatments, beyond its convenient dosing. She also inquired about what to expect from the upcoming preclinical data for ABCL575 being presented at a medical meeting.
Answer
President and CEO Dr. Carl L. Hansen explained that for ABCL635, the Phase I study will assess safety, key biomarkers for target engagement, and early efficacy, which should provide significant insight by mid-2026. He emphasized differentiation through a potentially cleaner safety profile and a once-monthly dosing preferred by a majority of women in their market research. For ABCL575, Dr. Hansen stated the upcoming data will include early animal work and, most importantly, PK analysis supporting a differentiated dosing regimen of at least three, and possibly six, months.